Summary
|
|
---|---|
EudraCT Number: | 2019-001755-39 |
Sponsor's Protocol Code Number: | ACE-LY-312(D8227C00001) |
National Competent Authority: | Germany - BfArM |
Clinical Trial Type: | EEA CTA |
Trial Status: | Ongoing |
Date on which this record was first entered in the EudraCT database: | 2020-09-01 |
Trial results |
Expand All
Collapse All
A. Protocol Information
|
|||
---|---|---|---|
A.1 | Member State Concerned | Germany - BfArM | |
A.2 | EudraCT number | 2019-001755-39 | |
A.3 | Full title of the trial |
|
|
A.3.1 | Title of the trial for lay people, in easily understood, i.e. non-technical, language |
|
|
A.3.2 | Name or abbreviated title of the trial where available |
|
|
A.4.1 | Sponsor's protocol code number | ACE-LY-312(D8227C00001) | |
A.7 | Trial is part of a Paediatric Investigation Plan | No | |
A.8 | EMA Decision number of Paediatric Investigation Plan |
B. Sponsor Information
|
||
---|---|---|
B.Sponsor: 1 | ||
B.1.1 | Name of Sponsor | Acerta Pharma B.V. (A Member of the AstraZeneca Group) |
B.1.3.4 | Country | Netherlands |
B.3.1 and B.3.2 | Status of the sponsor | Commercial |
B.4 Source(s) of Monetary or Material Support for the clinical trial: | ||
B.4.1 | Name of organisation providing support | AstraZeneca |
B.4.2 | Country | United Kingdom |
B.5 Contact point designated by the sponsor for further information on the trial | ||
B.5.1 | Name of organisation | AstraZeneca Clinical |
B.5.2 | Functional name of contact point | Clinical Study Information Center |
B.5.3 | Address: | |
B.5.3.1 | Street Address | n/a |
B.5.3.2 | Town/ city | n/a |
B.5.3.3 | Post code | n/a |
B.5.3.4 | Country | United States |
B.5.4 | Telephone number | +1877-240-9479 |
B.5.6 | information.center@astrazeneca.com |
D. IMP Identification
|
||
---|---|---|
D.IMP: 1 | ||
D.1.2 and D.1.3 | IMP Role | Test |
D.2 | Status of the IMP to be used in the clinical trial | |
D.2.1 | IMP to be used in the trial has a marketing authorisation | No |
D.2.5 | The IMP has been designated in this indication as an orphan drug in the Community | No |
D.2.5.1 | Orphan drug designation number | |
D.3 Description of the IMP | ||
D.3.1 | Product name | acalabrutinib |
D.3.2 | Product code | ACP-196 |
D.3.4 | Pharmaceutical form | Capsule, hard |
D.3.4.1 | Specific paediatric formulation | No |
D.3.7 | Routes of administration for this IMP | Oral use |
D.3.8 to D.3.10 IMP Identification Details (Active Substances) | ||
D.3.8 | INN - Proposed INN | acalabrutinib |
D.3.9.1 | CAS number | 1420477-60-6 |
D.3.9.2 | Current sponsor code | ACP-196 |
D.3.10 | Strength | |
D.3.10.1 | Concentration unit | mg milligram(s) |
D.3.10.2 | Concentration type | equal |
D.3.10.3 | Concentration number | 100 |
D.3.11 The IMP contains an: | ||
D.3.11.1 | Active substance of chemical origin | Yes |
D.3.11.2 | Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) | No |
The IMP is a: | ||
D.3.11.3 | Advanced Therapy IMP (ATIMP) | No |
D.3.11.3.1 | Somatic cell therapy medicinal product | No |
D.3.11.3.2 | Gene therapy medical product | No |
D.3.11.3.3 | Tissue Engineered Product | No |
D.3.11.3.4 | Combination ATIMP (i.e. one involving a medical device) | No |
D.3.11.3.5 | Committee on Advanced therapies (CAT) has issued a classification for this product | No |
D.3.11.4 | Combination product that includes a device, but does not involve an Advanced Therapy | No |
D.3.11.5 | Radiopharmaceutical medicinal product | No |
D.3.11.6 | Immunological medicinal product (such as vaccine, allergen, immune serum) | No |
D.3.11.7 | Plasma derived medicinal product | No |
D.3.11.8 | Extractive medicinal product | No |
D.3.11.9 | Recombinant medicinal product | No |
D.3.11.10 | Medicinal product containing genetically modified organisms | No |
D.3.11.11 | Herbal medicinal product | No |
D.3.11.12 | Homeopathic medicinal product | No |
D.3.11.13 | Another type of medicinal product | No |
D.IMP: 2 | ||
D.1.2 and D.1.3 | IMP Role | Test |
D.2 | Status of the IMP to be used in the clinical trial | |
D.2.1 | IMP to be used in the trial has a marketing authorisation | Yes |
D.2.1.1.1 | Trade name | MabThera 500 mg concentrate for solution for infusion |
D.2.1.1.2 | Name of the Marketing Authorisation holder | Roche Registration GmbH |
D.2.1.2 | Country which granted the Marketing Authorisation | European Union |
D.2.5 | The IMP has been designated in this indication as an orphan drug in the Community | No |
D.2.5.1 | Orphan drug designation number | |
D.3 Description of the IMP | ||
D.3.1 | Product name | rituximab |
D.3.2 | Product code | L01X C02 |
D.3.4 | Pharmaceutical form | Concentrate for solution for infusion |
D.3.4.1 | Specific paediatric formulation | No |
D.3.7 | Routes of administration for this IMP | Intravenous use |
D.3.8 to D.3.10 IMP Identification Details (Active Substances) | ||
D.3.8 | INN - Proposed INN | RITUXIMAB |
D.3.9.1 | CAS number | 174722-31-7 |
D.3.9.4 | EV Substance Code | SUB12570MIG |
D.3.10 | Strength | |
D.3.10.1 | Concentration unit | mg milligram(s) |
D.3.10.2 | Concentration type | equal |
D.3.10.3 | Concentration number | 500 |
D.3.11 The IMP contains an: | ||
D.3.11.1 | Active substance of chemical origin | No |
D.3.11.2 | Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) | Yes |
The IMP is a: | ||
D.3.11.3 | Advanced Therapy IMP (ATIMP) | No |
D.3.11.3.1 | Somatic cell therapy medicinal product | No |
D.3.11.3.2 | Gene therapy medical product | No |
D.3.11.3.3 | Tissue Engineered Product | No |
D.3.11.3.4 | Combination ATIMP (i.e. one involving a medical device) | No |
D.3.11.3.5 | Committee on Advanced therapies (CAT) has issued a classification for this product | No |
D.3.11.4 | Combination product that includes a device, but does not involve an Advanced Therapy | No |
D.3.11.5 | Radiopharmaceutical medicinal product | No |
D.3.11.6 | Immunological medicinal product (such as vaccine, allergen, immune serum) | No |
D.3.11.7 | Plasma derived medicinal product | No |
D.3.11.8 | Extractive medicinal product | No |
D.3.11.9 | Recombinant medicinal product | Yes |
D.3.11.10 | Medicinal product containing genetically modified organisms | No |
D.3.11.11 | Herbal medicinal product | No |
D.3.11.12 | Homeopathic medicinal product | No |
D.3.11.13 | Another type of medicinal product | No |
D.IMP: 3 | ||
D.1.2 and D.1.3 | IMP Role | Test |
D.2 | Status of the IMP to be used in the clinical trial | |
D.2.1 | IMP to be used in the trial has a marketing authorisation | Yes |
D.2.1.1.1 | Trade name | Endoxan 500 mg Powder for solution for injection |
D.2.1.1.2 | Name of the Marketing Authorisation holder | Baxter Oncology GmbH |
D.2.1.2 | Country which granted the Marketing Authorisation | Germany |
D.2.5 | The IMP has been designated in this indication as an orphan drug in the Community | No |
D.2.5.1 | Orphan drug designation number | |
D.3 Description of the IMP | ||
D.3.1 | Product name | cyclophosphamide |
D.3.4 | Pharmaceutical form | Powder for solution for injection |
D.3.4.1 | Specific paediatric formulation | No |
D.3.7 | Routes of administration for this IMP | Intravenous use |
D.3.8 to D.3.10 IMP Identification Details (Active Substances) | ||
D.3.8 | INN - Proposed INN | cyclophosphamide |
D.3.9.1 | CAS number | 6055-19-2 |
D.3.9.3 | Other descriptive name | CYCLOPHOSPHAMIDE MONOHYDRATE |
D.3.9.4 | EV Substance Code | SUB16414MIG |
D.3.10 | Strength | |
D.3.10.1 | Concentration unit | mg milligram(s) |
D.3.10.2 | Concentration type | equal |
D.3.10.3 | Concentration number | 500 |
D.3.11 The IMP contains an: | ||
D.3.11.1 | Active substance of chemical origin | Yes |
D.3.11.2 | Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) | No |
The IMP is a: | ||
D.3.11.3 | Advanced Therapy IMP (ATIMP) | No |
D.3.11.3.1 | Somatic cell therapy medicinal product | No |
D.3.11.3.2 | Gene therapy medical product | No |
D.3.11.3.3 | Tissue Engineered Product | No |
D.3.11.3.4 | Combination ATIMP (i.e. one involving a medical device) | No |
D.3.11.3.5 | Committee on Advanced therapies (CAT) has issued a classification for this product | No |
D.3.11.4 | Combination product that includes a device, but does not involve an Advanced Therapy | No |
D.3.11.5 | Radiopharmaceutical medicinal product | No |
D.3.11.6 | Immunological medicinal product (such as vaccine, allergen, immune serum) | No |
D.3.11.7 | Plasma derived medicinal product | No |
D.3.11.8 | Extractive medicinal product | No |
D.3.11.9 | Recombinant medicinal product | No |
D.3.11.10 | Medicinal product containing genetically modified organisms | No |
D.3.11.11 | Herbal medicinal product | No |
D.3.11.12 | Homeopathic medicinal product | No |
D.3.11.13 | Another type of medicinal product | No |
D.IMP: 4 | ||
D.1.2 and D.1.3 | IMP Role | Test |
D.2 | Status of the IMP to be used in the clinical trial | |
D.2.1 | IMP to be used in the trial has a marketing authorisation | Yes |
D.2.1.1.1 | Trade name | Ribodoxo 2 mg/ml solution for infusion |
D.2.1.1.2 | Name of the Marketing Authorisation holder | Hikma Farmacêutica (Portugal) S.A. |
D.2.1.2 | Country which granted the Marketing Authorisation | Germany |
D.2.5 | The IMP has been designated in this indication as an orphan drug in the Community | No |
D.2.5.1 | Orphan drug designation number | |
D.3 Description of the IMP | ||
D.3.1 | Product name | doxorubicin |
D.3.4 | Pharmaceutical form | Solution for infusion |
D.3.4.1 | Specific paediatric formulation | No |
D.3.7 | Routes of administration for this IMP | Intravenous use |
D.3.8 to D.3.10 IMP Identification Details (Active Substances) | ||
D.3.8 | INN - Proposed INN | Doxorubicin Hydrochloride |
D.3.9.1 | CAS number | 23214-92-8 |
D.3.9.4 | EV Substance Code | SUB01827MIG |
D.3.10 | Strength | |
D.3.10.1 | Concentration unit | mg/ml milligram(s)/millilitre |
D.3.10.2 | Concentration type | equal |
D.3.10.3 | Concentration number | 2 |
D.3.11 The IMP contains an: | ||
D.3.11.1 | Active substance of chemical origin | Yes |
D.3.11.2 | Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) | No |
The IMP is a: | ||
D.3.11.3 | Advanced Therapy IMP (ATIMP) | No |
D.3.11.3.1 | Somatic cell therapy medicinal product | No |
D.3.11.3.2 | Gene therapy medical product | No |
D.3.11.3.3 | Tissue Engineered Product | No |
D.3.11.3.4 | Combination ATIMP (i.e. one involving a medical device) | No |
D.3.11.3.5 | Committee on Advanced therapies (CAT) has issued a classification for this product | No |
D.3.11.4 | Combination product that includes a device, but does not involve an Advanced Therapy | No |
D.3.11.5 | Radiopharmaceutical medicinal product | No |
D.3.11.6 | Immunological medicinal product (such as vaccine, allergen, immune serum) | No |
D.3.11.7 | Plasma derived medicinal product | No |
D.3.11.8 | Extractive medicinal product | No |
D.3.11.9 | Recombinant medicinal product | No |
D.3.11.10 | Medicinal product containing genetically modified organisms | No |
D.3.11.11 | Herbal medicinal product | No |
D.3.11.12 | Homeopathic medicinal product | No |
D.3.11.13 | Another type of medicinal product | No |
D.IMP: 5 | ||
D.1.2 and D.1.3 | IMP Role | Test |
D.2 | Status of the IMP to be used in the clinical trial | |
D.2.1 | IMP to be used in the trial has a marketing authorisation | Yes |
D.2.1.1.1 | Trade name | Vincristinesulfat-TEVA 1 mg/ml Injectable solution |
D.2.1.1.2 | Name of the Marketing Authorisation holder | TEVA GmbH |
D.2.1.2 | Country which granted the Marketing Authorisation | Germany |
D.2.5 | The IMP has been designated in this indication as an orphan drug in the Community | No |
D.2.5.1 | Orphan drug designation number | |
D.3 Description of the IMP | ||
D.3.1 | Product name | vincristine |
D.3.4 | Pharmaceutical form | Solution for injection |
D.3.4.1 | Specific paediatric formulation | No |
D.3.7 | Routes of administration for this IMP | Intravenous use |
D.3.8 to D.3.10 IMP Identification Details (Active Substances) | ||
D.3.8 | INN - Proposed INN | vincristine |
D.3.9.1 | CAS number | 2068-78-2 |
D.3.9.3 | Other descriptive name | VINCRISTINE SULFATE |
D.3.9.4 | EV Substance Code | SUB05101MIG |
D.3.10 | Strength | |
D.3.10.1 | Concentration unit | mg/ml milligram(s)/millilitre |
D.3.10.2 | Concentration type | equal |
D.3.10.3 | Concentration number | 1 |
D.3.11 The IMP contains an: | ||
D.3.11.1 | Active substance of chemical origin | Yes |
D.3.11.2 | Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) | No |
The IMP is a: | ||
D.3.11.3 | Advanced Therapy IMP (ATIMP) | No |
D.3.11.3.1 | Somatic cell therapy medicinal product | No |
D.3.11.3.2 | Gene therapy medical product | No |
D.3.11.3.3 | Tissue Engineered Product | No |
D.3.11.3.4 | Combination ATIMP (i.e. one involving a medical device) | No |
D.3.11.3.5 | Committee on Advanced therapies (CAT) has issued a classification for this product | No |
D.3.11.4 | Combination product that includes a device, but does not involve an Advanced Therapy | No |
D.3.11.5 | Radiopharmaceutical medicinal product | No |
D.3.11.6 | Immunological medicinal product (such as vaccine, allergen, immune serum) | No |
D.3.11.7 | Plasma derived medicinal product | No |
D.3.11.8 | Extractive medicinal product | No |
D.3.11.9 | Recombinant medicinal product | No |
D.3.11.10 | Medicinal product containing genetically modified organisms | No |
D.3.11.11 | Herbal medicinal product | No |
D.3.11.12 | Homeopathic medicinal product | No |
D.3.11.13 | Another type of medicinal product | No |
D.IMP: 6 | ||
D.1.2 and D.1.3 | IMP Role | Test |
D.2 | Status of the IMP to be used in the clinical trial | |
D.2.1 | IMP to be used in the trial has a marketing authorisation | Yes |
D.2.1.1.1 | Trade name | Prednisone HEXAL 20 mg tablets |
D.2.1.1.2 | Name of the Marketing Authorisation holder | Hexal AG |
D.2.1.2 | Country which granted the Marketing Authorisation | Germany |
D.2.5 | The IMP has been designated in this indication as an orphan drug in the Community | No |
D.2.5.1 | Orphan drug designation number | |
D.3 Description of the IMP | ||
D.3.1 | Product name | prednisone |
D.3.4 | Pharmaceutical form | Tablet |
D.3.4.1 | Specific paediatric formulation | No |
D.3.7 | Routes of administration for this IMP | Oral use |
D.3.8 to D.3.10 IMP Identification Details (Active Substances) | ||
D.3.8 | INN - Proposed INN | prednisone |
D.3.9.3 | Other descriptive name | PREDNISONE |
D.3.9.4 | EV Substance Code | SUB10020MIG |
D.3.10 | Strength | |
D.3.10.1 | Concentration unit | mg milligram(s) |
D.3.10.2 | Concentration type | equal |
D.3.10.3 | Concentration number | 20 |
D.3.11 The IMP contains an: | ||
D.3.11.1 | Active substance of chemical origin | Yes |
D.3.11.2 | Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) | No |
The IMP is a: | ||
D.3.11.3 | Advanced Therapy IMP (ATIMP) | No |
D.3.11.3.1 | Somatic cell therapy medicinal product | No |
D.3.11.3.2 | Gene therapy medical product | No |
D.3.11.3.3 | Tissue Engineered Product | No |
D.3.11.3.4 | Combination ATIMP (i.e. one involving a medical device) | No |
D.3.11.3.5 | Committee on Advanced therapies (CAT) has issued a classification for this product | No |
D.3.11.4 | Combination product that includes a device, but does not involve an Advanced Therapy | No |
D.3.11.5 | Radiopharmaceutical medicinal product | No |
D.3.11.6 | Immunological medicinal product (such as vaccine, allergen, immune serum) | No |
D.3.11.7 | Plasma derived medicinal product | No |
D.3.11.8 | Extractive medicinal product | No |
D.3.11.9 | Recombinant medicinal product | No |
D.3.11.10 | Medicinal product containing genetically modified organisms | No |
D.3.11.11 | Herbal medicinal product | No |
D.3.11.12 | Homeopathic medicinal product | No |
D.3.11.13 | Another type of medicinal product | No |
D.IMP: 7 | ||
D.1.2 and D.1.3 | IMP Role | Test |
D.2 | Status of the IMP to be used in the clinical trial | |
D.2.1 | IMP to be used in the trial has a marketing authorisation | Yes |
D.2.1.1.1 | Trade name | Cellcristin 1mg/ml Injectable solution |
D.2.1.1.2 | Name of the Marketing Authorisation holder | Stadapharm GmbH |
D.2.1.2 | Country which granted the Marketing Authorisation | Germany |
D.2.5 | The IMP has been designated in this indication as an orphan drug in the Community | No |
D.2.5.1 | Orphan drug designation number | |
D.3 Description of the IMP | ||
D.3.1 | Product name | vincristine |
D.3.4 | Pharmaceutical form | Solution for injection |
D.3.4.1 | Specific paediatric formulation | No |
D.3.7 | Routes of administration for this IMP | Intravenous use |
D.3.8 to D.3.10 IMP Identification Details (Active Substances) | ||
D.3.8 | INN - Proposed INN | vincristine |
D.3.9.1 | CAS number | 2068-78-2 |
D.3.9.3 | Other descriptive name | VINCRISTINE SULFATE |
D.3.9.4 | EV Substance Code | SUB05101MIG |
D.3.10 | Strength | |
D.3.10.1 | Concentration unit | mg/ml milligram(s)/millilitre |
D.3.10.2 | Concentration type | equal |
D.3.10.3 | Concentration number | 1 |
D.3.11 The IMP contains an: | ||
D.3.11.1 | Active substance of chemical origin | Yes |
D.3.11.2 | Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) | No |
The IMP is a: | ||
D.3.11.3 | Advanced Therapy IMP (ATIMP) | No |
D.3.11.3.1 | Somatic cell therapy medicinal product | No |
D.3.11.3.2 | Gene therapy medical product | No |
D.3.11.3.3 | Tissue Engineered Product | No |
D.3.11.3.4 | Combination ATIMP (i.e. one involving a medical device) | No |
D.3.11.3.5 | Committee on Advanced therapies (CAT) has issued a classification for this product | No |
D.3.11.4 | Combination product that includes a device, but does not involve an Advanced Therapy | No |
D.3.11.5 | Radiopharmaceutical medicinal product | No |
D.3.11.6 | Immunological medicinal product (such as vaccine, allergen, immune serum) | No |
D.3.11.7 | Plasma derived medicinal product | No |
D.3.11.8 | Extractive medicinal product | No |
D.3.11.9 | Recombinant medicinal product | No |
D.3.11.10 | Medicinal product containing genetically modified organisms | No |
D.3.11.11 | Herbal medicinal product | No |
D.3.11.12 | Homeopathic medicinal product | No |
D.3.11.13 | Another type of medicinal product | No |
D.IMP: 8 | ||
D.1.2 and D.1.3 | IMP Role | Test |
D.2 | Status of the IMP to be used in the clinical trial | |
D.2.1 | IMP to be used in the trial has a marketing authorisation | Yes |
D.2.1.1.1 | Trade name | Oncovin 2 mg Injectionslösung |
D.2.1.1.2 | Name of the Marketing Authorisation holder | STADA Arzneimittel GmbH |
D.2.1.2 | Country which granted the Marketing Authorisation | Austria |
D.2.5 | The IMP has been designated in this indication as an orphan drug in the Community | No |
D.2.5.1 | Orphan drug designation number | |
D.3 Description of the IMP | ||
D.3.1 | Product name | vincristine |
D.3.4 | Pharmaceutical form | Solution for injection |
D.3.4.1 | Specific paediatric formulation | No |
D.3.7 | Routes of administration for this IMP | Intravenous use |
D.3.8 to D.3.10 IMP Identification Details (Active Substances) | ||
D.3.8 | INN - Proposed INN | vincristine |
D.3.9.1 | CAS number | 2068-78-2 |
D.3.9.3 | Other descriptive name | VINCRISTINE SULFATE |
D.3.9.4 | EV Substance Code | SUB05101MIG |
D.3.10 | Strength | |
D.3.10.1 | Concentration unit | mg/ml milligram(s)/millilitre |
D.3.10.2 | Concentration type | equal |
D.3.10.3 | Concentration number | 1 |
D.3.11 The IMP contains an: | ||
D.3.11.1 | Active substance of chemical origin | Yes |
D.3.11.2 | Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) | No |
The IMP is a: | ||
D.3.11.3 | Advanced Therapy IMP (ATIMP) | No |
D.3.11.3.1 | Somatic cell therapy medicinal product | No |
D.3.11.3.2 | Gene therapy medical product | No |
D.3.11.3.3 | Tissue Engineered Product | No |
D.3.11.3.4 | Combination ATIMP (i.e. one involving a medical device) | No |
D.3.11.3.5 | Committee on Advanced therapies (CAT) has issued a classification for this product | No |
D.3.11.4 | Combination product that includes a device, but does not involve an Advanced Therapy | No |
D.3.11.5 | Radiopharmaceutical medicinal product | No |
D.3.11.6 | Immunological medicinal product (such as vaccine, allergen, immune serum) | No |
D.3.11.7 | Plasma derived medicinal product | No |
D.3.11.8 | Extractive medicinal product | No |
D.3.11.9 | Recombinant medicinal product | No |
D.3.11.10 | Medicinal product containing genetically modified organisms | No |
D.3.11.11 | Herbal medicinal product | No |
D.3.11.12 | Homeopathic medicinal product | No |
D.3.11.13 | Another type of medicinal product | No |
D.IMP: 9 | ||
D.1.2 and D.1.3 | IMP Role | Test |
D.2 | Status of the IMP to be used in the clinical trial | |
D.2.1 | IMP to be used in the trial has a marketing authorisation | Yes |
D.2.1.1.1 | Trade name | Prednisone 20 mg Galen tablets |
D.2.1.1.2 | Name of the Marketing Authorisation holder | Galenpharma GmbH |
D.2.1.2 | Country which granted the Marketing Authorisation | Germany |
D.2.5 | The IMP has been designated in this indication as an orphan drug in the Community | No |
D.2.5.1 | Orphan drug designation number | |
D.3 Description of the IMP | ||
D.3.1 | Product name | prednisone |
D.3.4 | Pharmaceutical form | Tablet |
D.3.4.1 | Specific paediatric formulation | No |
D.3.7 | Routes of administration for this IMP | Oral use |
D.3.8 to D.3.10 IMP Identification Details (Active Substances) | ||
D.3.8 | INN - Proposed INN | prednisone |
D.3.9.3 | Other descriptive name | PREDNISONE |
D.3.9.4 | EV Substance Code | SUB10020MIG |
D.3.10 | Strength | |
D.3.10.1 | Concentration unit | mg milligram(s) |
D.3.10.2 | Concentration type | equal |
D.3.10.3 | Concentration number | 20 |
D.3.11 The IMP contains an: | ||
D.3.11.1 | Active substance of chemical origin | Yes |
D.3.11.2 | Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) | No |
The IMP is a: | ||
D.3.11.3 | Advanced Therapy IMP (ATIMP) | No |
D.3.11.3.1 | Somatic cell therapy medicinal product | No |
D.3.11.3.2 | Gene therapy medical product | No |
D.3.11.3.3 | Tissue Engineered Product | No |
D.3.11.3.4 | Combination ATIMP (i.e. one involving a medical device) | No |
D.3.11.3.5 | Committee on Advanced therapies (CAT) has issued a classification for this product | No |
D.3.11.4 | Combination product that includes a device, but does not involve an Advanced Therapy | No |
D.3.11.5 | Radiopharmaceutical medicinal product | No |
D.3.11.6 | Immunological medicinal product (such as vaccine, allergen, immune serum) | No |
D.3.11.7 | Plasma derived medicinal product | No |
D.3.11.8 | Extractive medicinal product | No |
D.3.11.9 | Recombinant medicinal product | No |
D.3.11.10 | Medicinal product containing genetically modified organisms | No |
D.3.11.11 | Herbal medicinal product | No |
D.3.11.12 | Homeopathic medicinal product | No |
D.3.11.13 | Another type of medicinal product | No |
D.8 Information on Placebo
|
||
---|---|---|
D.8 Placebo: 1 | ||
D.8.1 | Is a Placebo used in this Trial? | Yes |
D.8.3 | Pharmaceutical form of the placebo | Capsule, hard |
D.8.4 | Route of administration of the placebo | Oral use |
E. General Information on the Trial
|
|||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
E.1 Medical condition or disease under investigation | |||||||||||||||||||||||||
E.1.1 | Medical condition(s) being investigated |
|
|||||||||||||||||||||||
E.1.1.1 | Medical condition in easily understood language |
|
|||||||||||||||||||||||
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] | |||||||||||||||||||||||
MedDRA Classification | |||||||||||||||||||||||||
E.1.2 Medical condition or disease under investigation | |||||||||||||||||||||||||
|
|||||||||||||||||||||||||
E.1.3 | Condition being studied is a rare disease | No | |||||||||||||||||||||||
E.2 Objective of the trial | |||||||||||||||||||||||||
E.2.1 | Main objective of the trial |
|
|||||||||||||||||||||||
E.2.2 | Secondary objectives of the trial |
|
|||||||||||||||||||||||
E.2.3 | Trial contains a sub-study | No | |||||||||||||||||||||||
E.3 | Principal inclusion criteria |
|
|||||||||||||||||||||||
E.4 | Principal exclusion criteria |
|
|||||||||||||||||||||||
E.5 End points | |||||||||||||||||||||||||
E.5.1 | Primary end point(s) |
|
|||||||||||||||||||||||
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
|||||||||||||||||||||||
E.5.2 | Secondary end point(s) |
|
|||||||||||||||||||||||
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
|||||||||||||||||||||||
E.6 and E.7 Scope of the trial | |||||||||||||||||||||||||
E.6 | Scope of the trial | ||||||||||||||||||||||||
E.6.1 | Diagnosis | No | |||||||||||||||||||||||
E.6.2 | Prophylaxis | No | |||||||||||||||||||||||
E.6.3 | Therapy | Yes | |||||||||||||||||||||||
E.6.4 | Safety | Yes | |||||||||||||||||||||||
E.6.5 | Efficacy | Yes | |||||||||||||||||||||||
E.6.6 | Pharmacokinetic | Yes | |||||||||||||||||||||||
E.6.7 | Pharmacodynamic | Yes | |||||||||||||||||||||||
E.6.8 | Bioequivalence | No | |||||||||||||||||||||||
E.6.9 | Dose response | No | |||||||||||||||||||||||
E.6.10 | Pharmacogenetic | No | |||||||||||||||||||||||
E.6.11 | Pharmacogenomic | No | |||||||||||||||||||||||
E.6.12 | Pharmacoeconomic | No | |||||||||||||||||||||||
E.6.13 | Others | No | |||||||||||||||||||||||
E.7 | Trial type and phase | ||||||||||||||||||||||||
E.7.1 | Human pharmacology (Phase I) | No | |||||||||||||||||||||||
E.7.1.1 | First administration to humans | No | |||||||||||||||||||||||
E.7.1.2 | Bioequivalence study | No | |||||||||||||||||||||||
E.7.1.3 | Other | No | |||||||||||||||||||||||
E.7.1.3.1 | Other trial type description | ||||||||||||||||||||||||
E.7.2 | Therapeutic exploratory (Phase II) | No | |||||||||||||||||||||||
E.7.3 | Therapeutic confirmatory (Phase III) | Yes | |||||||||||||||||||||||
E.7.4 | Therapeutic use (Phase IV) | No | |||||||||||||||||||||||
E.8 Design of the trial | |||||||||||||||||||||||||
E.8.1 | Controlled | Yes | |||||||||||||||||||||||
E.8.1.1 | Randomised | Yes | |||||||||||||||||||||||
E.8.1.2 | Open | No | |||||||||||||||||||||||
E.8.1.3 | Single blind | No | |||||||||||||||||||||||
E.8.1.4 | Double blind | Yes | |||||||||||||||||||||||
E.8.1.5 | Parallel group | Yes | |||||||||||||||||||||||
E.8.1.6 | Cross over | No | |||||||||||||||||||||||
E.8.1.7 | Other | No | |||||||||||||||||||||||
E.8.2 | Comparator of controlled trial | ||||||||||||||||||||||||
E.8.2.1 | Other medicinal product(s) | No | |||||||||||||||||||||||
E.8.2.2 | Placebo | Yes | |||||||||||||||||||||||
E.8.2.3 | Other | Yes | |||||||||||||||||||||||
E.8.2.3.1 | Comparator description |
|
|||||||||||||||||||||||
E.8.2.4 | Number of treatment arms in the trial | 2 | |||||||||||||||||||||||
E.8.3 | The trial involves single site in the Member State concerned | No | |||||||||||||||||||||||
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes | |||||||||||||||||||||||
E.8.4.1 | Number of sites anticipated in Member State concerned | 7 | |||||||||||||||||||||||
E.8.5 | The trial involves multiple Member States | Yes | |||||||||||||||||||||||
E.8.5.1 | Number of sites anticipated in the EEA | 87 | |||||||||||||||||||||||
E.8.6 Trial involving sites outside the EEA | |||||||||||||||||||||||||
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes | |||||||||||||||||||||||
E.8.6.2 | Trial being conducted completely outside of the EEA | No | |||||||||||||||||||||||
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
|||||||||||||||||||||||
E.8.7 | Trial has a data monitoring committee | Yes | |||||||||||||||||||||||
E.8.8 | Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial |
|
|||||||||||||||||||||||
E.8.9 Initial estimate of the duration of the trial | |||||||||||||||||||||||||
E.8.9.1 | In the Member State concerned years | 8 | |||||||||||||||||||||||
E.8.9.1 | In the Member State concerned months | 0 | |||||||||||||||||||||||
E.8.9.1 | In the Member State concerned days | 0 | |||||||||||||||||||||||
E.8.9.2 | In all countries concerned by the trial years | 8 | |||||||||||||||||||||||
E.8.9.2 | In all countries concerned by the trial months | 0 | |||||||||||||||||||||||
E.8.9.2 | In all countries concerned by the trial days | 0 |
F. Population of Trial Subjects
|
|||
---|---|---|---|
F.1 Age Range | |||
F.1.1 | Trial has subjects under 18 | No | |
F.1.1.1 | In Utero | No | |
F.1.1.2 | Preterm newborn infants (up to gestational age < 37 weeks) | No | |
F.1.1.3 | Newborns (0-27 days) | No | |
F.1.1.4 | Infants and toddlers (28 days-23 months) | No | |
F.1.1.5 | Children (2-11years) | No | |
F.1.1.6 | Adolescents (12-17 years) | No | |
F.1.2 | Adults (18-64 years) | Yes | |
F.1.2.1 | Number of subjects for this age range: | 420 | |
F.1.3 | Elderly (>=65 years) | Yes | |
F.1.3.1 | Number of subjects for this age range: | 180 | |
F.2 Gender | |||
F.2.1 | Female | Yes | |
F.2.2 | Male | Yes | |
F.3 Group of trial subjects | |||
F.3.1 | Healthy volunteers | No | |
F.3.2 | Patients | Yes | |
F.3.3 | Specific vulnerable populations | Yes | |
F.3.3.1 | Women of childbearing potential not using contraception | No | |
F.3.3.2 | Women of child-bearing potential using contraception | Yes | |
F.3.3.3 | Pregnant women | No | |
F.3.3.4 | Nursing women | No | |
F.3.3.5 | Emergency situation | No | |
F.3.3.6 | Subjects incapable of giving consent personally | No | |
F.3.3.7 | Others | No | |
F.4 Planned number of subjects to be included | |||
F.4.1 | In the member state | 14 | |
F.4.2 | For a multinational trial | ||
F.4.2.1 | In the EEA | 195 | |
F.4.2.2 | In the whole clinical trial | 600 | |
F.5 | Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition) |
|
G. Investigator Networks to be involved in the Trial
|
||
---|---|---|
G.4 Investigator Network to be involved in the Trial: 1 | ||
G.4 Investigator Network to be involved in the Trial: 2 |
N. Review by the Competent Authority or Ethics Committee in the country concerned
|
||
---|---|---|
N. | Competent Authority Decision | Authorised |
N. | Date of Competent Authority Decision | 2020-10-16 |
N. | Ethics Committee Opinion of the trial application | Favourable |
N. | Ethics Committee Opinion: Reason(s) for unfavourable opinion |
|
N. | Date of Ethics Committee Opinion | 2020-11-30 |
P. End of Trial
|
||
---|---|---|
P. | End of Trial Status | Ongoing |